HSTO - Histogen stock down 8% after Q2 loss on track for six-day losing streak
- Shares of micro-cap clinical-stage therapeutics company Histogen ( NASDAQ: HSTO ) fell 8% to $1.95 in Friday afternoon trading, after the company reported a quarterly loss.
- The stock has been on a downward trend lately and, if today's losses hold, would post a sixth straight session in the red. From the close of Aug. 4 to yesterday, it has fallen 32% .
- San Diego, Calif.-based HSTO is advancing three clinical programs in hair growth, dermal fillers and joint cartilage repair.
- HSTO after hours on Thursday posted Q2 GAAP EPS of -$1.55.
- The company believes its existing cash and cash equivalents and cash inflow from operations would be sufficient to meet its anticipated cash needs through Dec. 2023.
- It closed a $5M private financing in July.
For further details see:
Histogen stock down 8% after Q2 loss, on track for six-day losing streak